Firstkind Ltd
26
2
3
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
19.2%
5 terminated/withdrawn out of 26 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
7%
1 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Cross Therapy Registry - Oedema - EU (CTR-Oedema-EU)
Role: lead
The RETRAIN Trial Phase 2
Role: lead
Neuromuscular Stimulation Versus Intermittent Compression for Venous Thromboembolism Prophylaxis in Critical Care
Role: collaborator
GEKO Venous Thromboembolism Prevention Study
Role: lead
Foot and Ankle Post-operative Oedema Management Using Geko™
Role: lead
Efficacy Study for Geko Device in VLU Patients (Canada)
Role: lead
Cross Therapy Registry - Edema - US
Role: lead
Geko™ Cross Therapy Registry - Wound
Role: lead
Efficacy of Adhesive Strength of New Hydrogel Formulation
Role: lead
Geko™ KM40C Hydrogel Skin Adhesion Trial (XW-3)
Role: lead
Efficacy Study for Geko Device in VLU Patients
Role: lead
Speckle Study: In Arterial, Mixed and Diabetic Foot Ulcers
Role: lead
Geko Neuromuscular Stimulator vs Thromboembolism Deterrent Stockings (TEDS): DVT Prevention Study
Role: lead
Study of gekoTM Interaction With Cardiac Pacemakers
Role: lead
A Study in Patients With Venous Leg Ulcers and Measuring the Effects of Using Geko™ Device
Role: lead
The Post-operative Effect on Formation of Oedema After Total Knee Arthroplasty With or Without the Use of a Nerve Stimulator (the gekoTM Device)
Role: collaborator
Lower Limb Blood Flow Geko vs Foot Pump
Role: collaborator
Geko Venous Leg Ulcer Study
Role: lead
Feasibility Study of the Use of the gekoTM Device for Faecal Incontinence in Older People Living at Home or in Care Homes
Role: lead
Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients
Role: lead